Literature DB >> 27162709

Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.

Daniel J O Roche1, Lara A Ray2, Megan M Yardley1, Andrea C King3.   

Abstract

There is a strong association between cigarette smoking and alcohol use at the epidemiological, behavioral, and molecular levels, and this co-use creates substantial impediments to smoking cessation among smokers who are also heavy drinkers. Compared with individuals who only smoke, those who both drink and smoke heavily experience more severe health consequences and have greater difficulty in quitting smoking. During smoking abstinence, greater alcohol use is associated with decreased odds of smoking cessation, and smokers are substantially more likely to experience a smoking lapse during drinking episodes. As heavy drinking smokers are less responsive to the currently available pharmacological treatments, this subgroup of high-risk substance users possesses a unique clinical profile and treatment needs. Thus, treatment development for heavy drinking smokers represents a significant and understudied research area within the field of smoking cessation. This review will briefly describe findings from epidemiological, behavioral, and molecular studies illustrating alcohol and tobacco co-use and identify how the behavioral and neurobiological mechanisms underlying the interaction of alcohol and nicotine may inform the development of targeted treatments for this unique population of smokers.

Entities:  

Keywords:  Heavy drinking smokers; alcohol use disorder; comorbidity; pharmacotherapy; tobacco use disorder; treatment

Year:  2016        PMID: 27162709      PMCID: PMC4859339          DOI: 10.1007/s40429-016-0081-3

Source DB:  PubMed          Journal:  Curr Addict Rep


  184 in total

Review 1.  Smoking and drinking as complementary behaviours.

Authors:  Robin Room
Journal:  Biomed Pharmacother       Date:  2004-03       Impact factor: 6.529

2.  Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption.

Authors:  Linzy M Hendrickson; Paul Gardner; Andrew R Tapper
Journal:  Channels (Austin)       Date:  2011-03-01       Impact factor: 2.581

3.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

4.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

5.  A randomized trial for hazardous drinking and smoking cessation for callers to a quitline.

Authors:  Benjamin A Toll; Steve Martino; Stephanie S O'Malley; Lisa M Fucito; Sherry A McKee; Christopher W Kahler; Alana M Rojewski; Martin C Mahoney; Ran Wu; Paula Celestino; Srinivasa Seshadri; James Koutsky; Andrew Hyland; K Michael Cummings
Journal:  J Consult Clin Psychol       Date:  2014-11-24

Review 6.  Nicotine receptor partial agonists for smoking cessation.

Authors:  Kate Cahill; Lindsay F Stead; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

7.  Alcohol-induced increases in smoking behavior for nicotinized and denicotinized cigarettes in men and women.

Authors:  Andrea King; Patrick McNamara; Megan Conrad; Dingcai Cao
Journal:  Psychopharmacology (Berl)       Date:  2009-11       Impact factor: 4.530

Review 8.  Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis.

Authors:  Edward J Mills; Ping Wu; Ian Lockhart; Kristian Thorlund; Milo Puhan; Jon O Ebbert
Journal:  Ann Med       Date:  2012-08-06       Impact factor: 4.709

9.  Risk factors for treatment failure in smokers: relationship to alcohol use and to lifetime history of an alcohol use disorder.

Authors:  Robert F Leeman; Sherry A McKee; Benjamin A Toll; Suchitra Krishnan-Sarin; Judith L Cooney; Robert W Makuch; Stephanie S O'Malley
Journal:  Nicotine Tob Res       Date:  2008-12       Impact factor: 4.244

10.  Effects of varenicline on abstinence and smoking reward following a programmed lapse.

Authors:  Erin A McClure; Ryan G Vandrey; Matthew W Johnson; Maxine L Stitzer
Journal:  Nicotine Tob Res       Date:  2012-05-09       Impact factor: 4.244

View more
  21 in total

1.  Cigarette Use Among Individuals with Alcohol Use Disorders in the United States, 2002 to 2016: Trends Overall and by Race/Ethnicity.

Authors:  Andrea H Weinberger; Lauren R Pacek; Daniel Giovenco; Sandro Galea; Michael J Zvolensky; Misato Gbedemah; Renee D Goodwin
Journal:  Alcohol Clin Exp Res       Date:  2018-12-10       Impact factor: 3.455

2.  Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.

Authors:  Aaron C Lim; Daniel J O Roche; Lara A Ray
Journal:  J Stud Alcohol Drugs       Date:  2018-11       Impact factor: 2.582

3.  Developing a model of limited-access nicotine consumption in C57Bl/6J mice.

Authors:  C R Kasten; A M Frazee; S L Boehm
Journal:  Pharmacol Biochem Behav       Date:  2016-05-27       Impact factor: 3.533

4.  Relationship between negative affect and smoking topography in heavy drinking smokers.

Authors:  ReJoyce Green; Spencer Bujarski; Daniel J O Roche; Lara A Ray
Journal:  Addict Behav       Date:  2016-05-18       Impact factor: 3.913

5.  Cigarette smoking quit rates among adults with and without alcohol use disorders and heavy alcohol use, 2002-2015: A representative sample of the United States population.

Authors:  Andrea H Weinberger; Misato Gbedemah; Renee D Goodwin
Journal:  Drug Alcohol Depend       Date:  2017-08-05       Impact factor: 4.492

6.  Psychiatric, Demographic, and Brain Morphological Predictors of Relapse After Treatment for an Alcohol Use Disorder.

Authors:  Timothy C Durazzo; Dieter J Meyerhoff
Journal:  Alcohol Clin Exp Res       Date:  2016-11-24       Impact factor: 3.455

7.  Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co- and tri-use.

Authors:  D J O Roche; S Bujarski; R Green; E E Hartwell; A M Leventhal; L A Ray
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

8.  Searching for Personalized Medicine for Binge Drinking Smokers: Smoking Cessation Using Varenicline, Nicotine Patch, or Combination Nicotine Replacement Therapy.

Authors:  Jesse T Kaye; Adrienne L Johnson; Timothy B Baker; Megan E Piper; Jessica W Cook
Journal:  J Stud Alcohol Drugs       Date:  2020-07       Impact factor: 2.582

9.  Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.

Authors:  Sarah E Maggio; Meredith A Saunders; Thomas A Baxter; Kimberly Nixon; Mark A Prendergast; Guangrong Zheng; Peter Crooks; Linda P Dwoskin; Rachel D Slack; Amy H Newman; Richard L Bell; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2018-02-18       Impact factor: 4.530

10.  Drinking Level Versus Drinking Pattern and Cigarette Smoking Among Older Adults.

Authors:  Charles J Holahan; Penny L Brennan; Kathleen K Schutte; Carole K Holahan; J Gregory Hixon; Rudolf H Moos
Journal:  Alcohol Clin Exp Res       Date:  2018-02-27       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.